संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - penicillin v potassium (unii: 146t0tu1jb) (penicillin v - unii:z61i075u2w) - penicillin v 125 mg in 5 ml - penicillin v potassium tablets and penicillin v potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin g-sensitive microorganisms. therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. note: severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin v during the acute stage. indicated surgical procedures should be performed. the following infections will usually respond to adequate dosage of penicillin v. streptococcal infections (without bacteremia). mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. note: streptococci in groups a, c, g, h, l, and m are very sensitive to penicillin. other groups, including group d (enterococcus), are resistant. pneumococcal infections. mild to moderately severe infections of the respiratory tract. staphylococcal infections —penicillin g-sensitive. mild infec

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

physicians total care, inc. - penicillin v potassium (unii: 146t0tu1jb) (penicillin v - unii:z61i075u2w) - penicillin v 125 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin v potassium tablets, penicillin v potassium for oral solution, and other antibacterial drugs, penicillin v potassium tablets and penicillin v potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. penicillin v potassium tablets and penicillin v potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin g-sensitive microorganisms. therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. note: severe pneumonia, empyema, bacteremia, pericarditis, meningi

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - penicillin v potassium (unii: 146t0tu1jb) (penicillin v - unii:z61i075u2w) - penicillin v 125 mg in 5 ml - penicillin v potassium tablets and penicillin v potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin g-sensitive microorganisms. therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. note: severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin v during the acute stage. indicated surgical procedures should be performed. the following infections will usually respond to adequate dosage of penicillin v. streptococcal infections (without bacteremia). mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. note: streptococci in groups a, c, g, h, l, and m are very sensitive to penicillin. other groups, including group d (enterococcus), are resistant. pneumococcal infections. mild to moderately severe infections of the respiratory tract. staphylococcal infections —penicillin g-sensitive. mild infec

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - penicillin v potassium (unii: 146t0tu1jb) (penicillin v - unii:z61i075u2w) - penicillin v 250 mg - penicillin v potassium tablets and penicillin v potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin g-sensitive microorganisms. therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. note: severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin v during the acute stage. indicated surgical procedures should be performed. the following infections will usually respond to adequate dosage of penicillin v. streptococcal infections (without bacteremia). mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. note: streptococci in groups a, c, g, h, l, and m are very sensitive to penicillin. other groups, including group d (enterococcus), are resistant. pneumococcal infections. mild to moderately severe infections of the respiratory tract. staphylococcal infections —penicillin g-sensitive. mild infec

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

physicians total care, inc. - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone sodium phosphate 1 mg in 1 ml - for the treatment of the following conditions: steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. epithelial herpes simplex keratitis (dendritic keratitis). acute infectious stages of vaccinia, varicella, and many other viral diseases of the cornea and conjunctiva. mycobacterial infection of the eye. fungal diseas

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate 500 mg - chloroquine phosphate tablets are indicated for suppressive treatment and for acute attacks of malaria due to p. vivax, p. malariae, p. ovale, and susceptible strains of p. falciparum. the drug is also indicated for the treatment of extraintestinal amebiasis. chloroquine phosphate tablets do not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. it is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. in patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of p. falciparum. use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds or to any oth

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

fresenius kabi usa, llc - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr), sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (phosphate ion - unii:nk08v8k8hr) - sodium phosphate, monobasic, monohydrate 276 mg in 1 ml - sodium phosphates injection, usp is indicated as a source of phosphate, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake.  it is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. the concomitant amount of sodium (4 meq/ml) must be calculated into total electrolyte dose of such prepared solutions. sodium phosphate is contraindicated in diseases where high phosphate or low calcium levels may be encountered, and in patients with hypernatremia.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

west-ward pharmaceutical corp - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate 250 mg - chloroquine phosphate tablets are indicated for suppressive treatment and for acute attacks of malaria due to p. vivax, p. malariae, p. ovale, and susceptible strains of p. falciparum. the drug is also indicated for the treatment of extraintestinal amebiasis. chloroquine phosphate tablets do not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. it is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. in patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of p. falciparum. use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds or to any oth

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - prednisolone sodium phosphate, quantity: 6.72 mg/ml (equivalent: prednisolone, qty 5 mg/ml) - oral liquid, solution - excipient ingredients: propylene glycol; dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate; disodium edetate; methyl hydroxybenzoate; propyl hydroxybenzoate; purified water - whenever corticosteroid therapy is indicated.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - prednisolone sodium phosphate, quantity: 6.72 mg/ml (equivalent: prednisolone, qty 5 mg/ml) - oral liquid, solution - excipient ingredients: disodium edetate; dibasic sodium phosphate; propyl hydroxybenzoate; sorbitol solution (70 per cent) (non-crystallising); methyl hydroxybenzoate; purified water; monobasic sodium phosphate; flavour - wherever corticosteroid therapy is indicated.